04-17-06

Express Mailing Label No.: EV 460337493 US Attorney Docket No. 33357-501 Date of Deposit: April 13, 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Shailubhai et al.

SERIAL NUMBER:

10/796,292

EXAMINER:

Cybille Delacroix Muirhe

FILING DATE:

March 10, 2004

ART UNIT:

1614

For:

METHOD OF TREATING CANCER WITH AZASPIRANE

COMPOSITIONS

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

- 1. Supplemental Information Disclosure Statement (2 pages);
- 2. Modified Form 1449/PTO (1 page), in duplicate;
- 3. Copies of Cited References: B1; C2-6; and
- 4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 33357-501. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529 Naomi S. Biswas, Reg. No. 38,384

Gregory J. Sieczkiewicz, Reg. No. 48,223

Attorneys for Applicant c/o MINTZ, LEVIN

Tel: (617) 542-6000 Fax: (617) 542-2241

Customer No. 30623

Date: April 13, 2006

TRA 2141693v.1

Express Mail Label No.: EV 460337493 US Attorney Docket No.: 33357-501

Date of Deposit: April 13, 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Shailubhai et al.

L NUMBER: 10/796,292 EXAMINER: Cybille Delacroix Muirhe

FILING DATE: March 10, 2004 ART UNIT: 1614

FOR: METHOD OF TREATING CANCER WITH AZASPIRANE

COMPOSITIONS

MAIL STOP AMENDMENT

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Information Disclosure Statement is being filed within three months of the mailing date of the Supplementary European Search Report for EP 04 71 9198, mailed March 8, 2006 in the above-identified case. Accordingly, no fee or certification is believed required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplementary Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANT:

Shailubhai et al.

U.S.S.N.:

10/796,292

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 33357-501.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529 Naomi S. Biswas, Reg. No. 38,384

Gregory J. Sieczkiewicz, Reg. No. 48,223

Attorneys for Applicant c/o MINTZ, LEVIN

Tel: (617) 542-6000 Fax: (617) 542-2241 **Customer No. 30623**

Date: April 13, 2006

TRA 2141681v.1



Express Mail No.: EV 460337493 US

Date of Deposit: April 13, 2006

Please type a plus sign (+) in this box

Page 1 of 1 Attorney Docket No.: 33357-501

PTO/SB (12-97)
Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

			Under the Papers	work Reduction Ac	:t of 1995, n	o persons are required to respond to a	collection of informat	tion unless it di	splays a valid O	MB control	number.
Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)						Application Number		10/796,292			
						Filing Date		March 10, 2004 Shailubhai			
						First Named Invento	or				
						Group Art Unit 1614					
						Examiner Name		Cybille Delacroix Muirhe			
						Attorney Docket Num	nber	33357-501			
					U.S	PATENT DOCUMENTS			•,5 • • •	- J.W.	7
Exam Initials			Patent ment No.	Issue Date	Name	Name of Patentee(s) or Applicant(s)		Class	Sub Class	Filing Date If Appropriate	
	<u> </u>										
Exam	Cite			U.S.II Published	Cin-al in this Active	UBLISHED APPLICATION DOCUMENTS Name of Patentee(s) or Applicant(s)		Class	Sub		5. V. 189
Initials	No.			Date	i ivai			Ciass	Class	Filing Date If Appropriate	
100 (100 (100 (100 (100 (100 (100 (100		12-16			FORE	IGN PATENT DOCUMENT	TS.				
Exam Initials	Cite No.	Forei Office	gn Patent Do Number	Name Name		ne of Patentee(s) or Applicant(s)		Date of Publication		Translation Yes No	
	В1	EP	0 753 512	: A1	SMITH	MITHKLINE BEECHAM CORPORATION		01/15/97			
. Jan				THED DOINE	NOT_	NON PATENT LITERATI	IDE DOCUME	NTC		123	and the same
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS											
Initials	No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.									
	C2	Mira	Mirabelli et al. Anti-Cancer Drug Design, 3(4):231-242 (1989)								
	СЗ	Rice et al. J. Med. Chem., 43:388-402 (1963)									
	C4	Rice et al. J. Med. Chem., 11(2):378-380 (1968)									
	C5	Rice et al. J. Heterocyclic Chem., 10(5):731-735 (1973)									
	C6	Supplementary European Search Report for EP 04 71 9198, mailed March 8, 2006.									
Serial No	o		, filed			previously cited by or su , and relied up and divisional application	oon for an ea				on,
Examiner Signature							Date Considered				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.